Immix Biopharma (IMMX) Total Current Liabilities (2020 - 2026)

Immix Biopharma (IMMX) has 7 years of Total Current Liabilities data on file, last reported at $10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 13.24% year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.5 million (up 13.24% YoY), and the FY2025 full-year result was $10.1 million, up 16.39% from the prior year.
• Total Current Liabilities improved to $10.5 million in Q1 2026, from $10.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $10.9 million in Q3 2025 to a low of $365086.0 in Q1 2022.
• A 5-year average of $5.3 million and a median of $3.9 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 530.22% in 2022 and climbed 13.24% in 2026, its largest moves.
• Tracing IMMX's Total Current Liabilities over 5 years: stood at $1.3 million in 2022, then surged by 192.3% to $3.7 million in 2023, then surged by 133.41% to $8.7 million in 2024, then gained by 16.39% to $10.1 million in 2025, then advanced by 4.24% to $10.5 million in 2026.
• Business Quant data shows IMMX's Total Current Liabilities at $10.5 million in Q1 2026, $10.1 million in Q4 2025, and $10.9 million in Q3 2025.